The two say they prefer committing themselves to their science and nothing else. Though they “tick a couple of boxes people are interested in,” they would much rather talk about their science instead of background. 

“Scientifically, it is highly likely that the immune response by this vaccine also can deal with the new virus variant,” said Ugur Sahin, co-founder of BioNTech